Skip to content
10-Q

Quarterly Report

KERYX BIOPHARMACEUTICALS INC

0001114220-18-000050

← back to feed
Filed
May 10, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2018 · Apr 30, 2018 120.44M sh
Capex Q1 2018 · Mar 31, 2018 $78K
Capex Q1 2018 · Mar 31, 2017 $0
Cash And Equivalents Q1 2018 · Mar 31, 2018 $60.09M
Cash And Equivalents Q1 2018 · Dec 31, 2017 $93.53M
Cash And Equivalents Q1 2018 · Mar 31, 2017 $90.91M
Cash And Equivalents Q1 2018 · Dec 31, 2016 $111.81M
Stockholders Equity Q1 2018 · Mar 31, 2018 −$31.61M
Stockholders Equity Q1 2018 · Dec 31, 2017 −$14.1M
Current Liabilities Q1 2018 · Mar 31, 2018 $44.92M
Current Liabilities Q1 2018 · Dec 31, 2017 $45.42M
Total Liabilities Q1 2018 · Mar 31, 2018 $171.73M
Total Liabilities Q1 2018 · Dec 31, 2017 $172.97M
Current Assets Q1 2018 · Mar 31, 2018 $119.55M
Current Assets Q1 2018 · Dec 31, 2017 $141.57M
Total Assets Q1 2018 · Mar 31, 2018 $140.12M
Total Assets Q1 2018 · Dec 31, 2017 $158.87M
Sga Expense Q1 2018 · Mar 31, 2018 $25.84M
Sga Expense Q1 2018 · Mar 31, 2017 $23.1M
Rd Expense Q1 2018 · Mar 31, 2018 $8.39M
Rd Expense Q1 2018 · Mar 31, 2017 $6.76M
Net Income Q1 2018 · Mar 31, 2018 −$21.9M
Net Income Q1 2018 · Mar 31, 2017 −$23.02M
Operating Income Q1 2018 · Mar 31, 2018 −$22.75M
Operating Income Q1 2018 · Mar 31, 2017 −$23.11M
Cost Of Revenue Q1 2018 · Mar 31, 2018 $9.6M
Cost Of Revenue Q1 2018 · Mar 31, 2017 $4.27M